2020 Year in Review - Non–Small-Cell Lung Cancer

Patients with untreated advanced NSCLC with EGFR mutations achieved improved progression-free survival with treatment with gefitinib and carboplatin plus pemetrexed compared with gefitinib alone. Read More ›

Researchers report higher overall response rate, median duration of response, and median progression-free survival in treatment-naïve patients with a MET exon 14 skipping mutation compared with previously treated patients. Read More ›

Researchers reported improved overall survival in patients with nonsquamous non–small-cell lung cancer with EGFR mutations. Read More ›

Tarloxotinib treatment was well tolerated and sizeable percentages of patients in both study cohorts achieved either partial response or stable disease. Read More ›

Overall response rate, duration of response, and media progression-free survival were highest in the group of treatment-naïve patients with T790M negativity and any MET mutation. Read More ›

Over the past year, the COVID-19 pandemic has ushered in unprecedented changes in the practice of medicine and dissemination of treatment advances presented in scientific forums. Read More ›

Improved progression-free survival and overall survival in patients who received upfront stereotactic radiotherapy and TKI treatment should prompt additional study. Read More ›

Previously untreated patients and those who had received prior intracranial radiotherapy responded to selpercatinib treatment. Read More ›

Treatment was well tolerated and also associated with delayed progression in previously treated patients with NSCLC and MET^Amp/Ex14Δ. Read More ›

Dual treatment with ramucirumab and erlotinib produced similar results in patients with ex21 and ex19 mutations. Read More ›